Introduction {#Sec1}
============

Circulating tumor markers such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) can be found in the blood of cancer patients. As a liquid biopsy, these markers complement solid biopsies and have the advantage of being physically more accessible and patient-friendly than traditional tissue biopsies. This provides a possibility for prognosis prediction, closer monitoring of treatment response and disease progression, identification of drug targets, as well as an opportunity for early detection of recurrence. The presence of CTCs in the blood of patients with primary breast cancer has been shown to be an independent predictor of decreased disease-free and overall survival \[[@CR1], [@CR2]\], but the treatment predictive value of the cells is still under debate \[[@CR3], [@CR4]\]. The CTC methodology in primary breast cancer is also limited by the low number of detected cells, which makes enumeration and evaluation statistically challenging \[[@CR5]\]. ctDNA, the cell-free DNA that originates from cancer cells, is a promising biomarker whose prognostic and treatment predictive power is emerging \[[@CR6], [@CR7]\]. Recent studies have shown that quantification of specific mutations in ctDNA can be associated with early detection of metastases and therapy resistance in breast cancer as well as in other diagnoses \[[@CR8]--[@CR12]\].

The risk that tumor cells are released into the bloodstream from a primary tumor during surgical interventions has been addressed in a few studies \[[@CR13]--[@CR17]\], although how and when tumor cells are shed as well as the clinical importance of this release is poorly understood \[[@CR18]\]. Animal studies have also found that physical manipulation of a primary tumor by applying pressure to it causes tumor cell dissemination \[[@CR19]--[@CR21]\]. We have previously investigated if mammographic breast compression in patients with an already present breast tumor could cause shedding of tumor cells to the peripheral circulation \[[@CR22]\]. We found no indications that this would be the case in a pilot study of 24 patients with primary breast cancer.

However, the configuration of the human blood circulation can cause tumor cells released from the breast to pass through the capillary vasculature of the lungs before reaching the peripheral blood vessels. In our previous study \[[@CR22]\], CTCs captured only in the peripheral blood might have resulted in an underestimation of CTC number. It has been shown that a higher number of CTCs can be found in central compared to peripheral venous blood in patients with metastatic breast cancer \[[@CR23]\] as well as in other diagnoses \[[@CR24]--[@CR26]\]. Animal studies of colon carcinoma cells have shown that the majority (80--100%) of tumor cells could be trapped in the capillary bed of the first organ they encounter \[[@CR27]\]. In breast cancer, an autopsy study by Peeters et al. \[[@CR28]\] showed that CTCs were trapped in the lung microvasculature in four of the nine patients who all had high CTC counts (\> 100). Thus, it is likely that the number of CTCs found in the peripheral blood system is not representative of a possible release of tumor cells from the primary tumor during manipulation such as breast compression during mammography or surgery. The difference in CTC number between central and peripheral blood is possibly even more pronounced after specific interventions compared to a more steady-state-like condition of metastatic disease \[[@CR24], [@CR26]\].

To our knowledge, ctDNA levels have not been used to study a possible release of tumor cells or tumor cell debris after breast compression or any other mechanical intervention in breast cancer. Relatively few studies have so far compared the levels of both CTCs and ctDNA in the same clinical patient cohort at identical time points and our understanding of the relationship between the two liquid tumor markers is limited. However, both the level of ctDNA and the number of CTCs have been shown to have a prognostic value in mainly metastatic breast cancer cohorts \[[@CR29], [@CR30]\]. Mutation analysis of ctDNA and single CTCs suggests that ctDNA reflects the heterogeneity of mutations found in individual CTCs \[[@CR30]\], but ctDNA levels have been found to have a higher correlation with tumor burden than CTCs \[[@CR29]\].

The aim of this study was to investigate how the presence of CTCs and ctDNA are affected by breast compression during mammography in patients with primary breast cancer. Special emphasis was made on comparing circulating tumor marker burden between the central and peripheral blood circulation.

Materials and methods {#Sec2}
=====================

Patient cohort and clinical parameters {#Sec3}
--------------------------------------

The patient cohort comprises preoperative patients within the ongoing SCAN-B trial (Clinical Trials ID NCT02306096) at Lund University and Skåne University Hospital, Sweden \[[@CR31], [@CR32]\]. During 2015--2016, 31 patients scheduled for neoadjuvant therapy volunteered to do an extra mammography after diagnosis and were included in the present study. The patient mean age was 51.9 years (range 33--74 years) and the mean compressed breast thickness and applied compression force during the examination were 55.8 mm (range 26.5--77.0 mm) and 103.4 N (range 71.5--123.1 N), respectively, as indicated by the mammography system (Mammomat Inspiration, Siemens Healthineers, Erlangen, Germany). All patients gave written informed consent and the study was approved by the Regional Ethical Review Board in Lund, Sweden (diary number 2014/521).

Clinical data including biomarker expression, histological subtype, and nodal status were retrieved from pathology reports and the patient's clinical charts. Information on biomarker expression was based on analysis from the core needle biopsy before initiation of neoadjuvant therapy. Estrogen receptor (ER) positivity was defined as ≥ 10% positive cancer cells, human epidermal growth factor receptor 2 (HER2) positivity was defined by immunohistochemistry (IHC) or in situ hybridization (ISH) as (IHC3+) or ISH-positive cells, and Ki67 positivity was defined as \> 20% positive cancer cells. Information from mammograms, ultrasound images, and breast tomosynthesis was compiled into one measure of tumor size.

Blood sampling {#Sec4}
--------------

All patients had a central venous access to allow administration of intravenous neoadjuvant chemotherapy, which enabled blood collection from superior vena cava, draining the breasts. A dedicated research nurse attended the patient during the mammography examination and acquired blood samples before and after mammographic breast compression, first from central venous access and secondly from a peripheral vein at both occasions. The median time for blood sampling after compression was 2 min (range 0--5 min) for central blood samples and 7 min (range 5--23) for peripheral blood samples. At each time point, 10 ml whole blood was collected in CellSave tubes (Menarini Silicon Biosystems, Bologna, Italy) for CTC analysis and 10 ml whole blood was collected in Cell-Free DNA Blood Collection Tubes (Streck Inc., Omaha, USA) for ctDNA analysis. The blood samples were transported at room temperature and subsequent analyses were performed within 96 h after sample taking.

CTC analysis {#Sec5}
------------

The blood samples were analyzed for CTC number using the FDA-approved CellSearch^©^ system (Menarini Silicon Biosystems). Briefly, a ferrofluid-conjugated epithelial cell adhesion molecule (EpCAM)-directed antibody was used to separate CTCs from the majority of white blood cells. Fluorescent staining with DAPI (nuclear staining), cytokeratin (CK) 8, 18, 19-directed PE-conjugated antibodies, and CD45-directed APC-conjugated antibodies were applied to identify CTCs (DAPI +/CK+/CD45--). Two independent and accredited technicians manually evaluated images of CK + events selected automatically by the CellTracks II system (Menarini Silicon Biosystems). The method has been described in detail elsewhere \[[@CR33]\]. Cut-off for CTC positivity was ≥ 1 CTC/7.5 ml blood as suggested by a recent review of primary breast cancer \[[@CR1]\].

ctDNA analysis {#Sec6}
--------------

Candidate somatic mutations for ctDNA measurement were obtained from RNA sequencing (RNA-seq) data generated within SCAN-B \[[@CR31], [@CR34]\]. Twenty-eight of the 31 patients had available tumor RNA-seq data. Sequencing, base calling, FASTQ file processing, and filtering were performed as previously described \[[@CR34]\]. Using a Snakemake workflow, reads in FASTQ format were aligned to the human reference genome GRCh38.p8 (including alternative sequences and decoys, and patched with dbSNP Build 147) using HISAT2 2.0.5 \[[@CR35]\] (with default options except \--rna-strandness RF, \--rg-id \${ID_NAME}, \--rg PL:illumina, \--rg PU:\${UNIT}, \--rg SM:\${SAMPLE}), and duplicate reads were marked using SAMBLASTER 0.1.24. Variants were called using VarDict-Java 1.5.0 \[[@CR36]\] (with default options except -f 0.02, -N \${SAMPLE}, -b \${BAM_FILE}, -c 1, -S 2, -E 3, -g 4, -Q 10, -r 2, -q 20), and annotated with dbSNP build 150 and COSMIC v84 using vcfanno 0.2.8 \[[@CR37]\].

From the RNA-seq mutation calling, one somatic mutation for each patient was selected for IBSAFE assay design for ultrasensitive mutation detection. IBSAFE^©^ (SAGA Diagnostics AB, Lund, Sweden) is an enhanced droplet digital PCR technology with significantly improved sensitivity and specificity, allowing for quantification of alleles to 0.001% mutant allele frequency (MAF) \[George et al. manuscript in preparation\]. IBSAFE assays targeting a somatic mutation were designed for 20 patients and the assays validated using 6 ng of corresponding tumor DNA as positive control and 180 ng of human normal genomic DNA (Promega, Madison, USA) as negative control, confirming a lower limit of detection of at least 0.0017% MAF for each assay.

Whole blood collected in Streck tubes were centrifuged at 2000×*g* for 15 min at room temperature to fractionate plasma, followed by clearing of the plasma fraction by centrifugation at 10,000×*g* for 15 min at 4 °C. Cell-free DNA was isolated using the QIAamp Circulating Nucleic Acid Kit or the QIAamp MinElute ccfDNA Midi Kit (Qiagen, Hilden, Germany), of which 20% of the eluate used for IBSAFE reactions and measurement of mutant and wild-type ctDNA copies and calculation of MAF.

Statistical analysis {#Sec7}
--------------------

Clinical and patient-specific characteristics were compared between patients that had ≥ 1 CTC/≥ 0.01% MAF present in any sample and patients with 0 CTCs/0% MAF in all samples. Agreement between CTC- and ctDNA-positive patients was analyzed using Cohen's kappa statistics. The Mann--Whitney U-test was used to compare the distribution of continuous variables. For categorical variables, Fisher's exact test was used in all comparisons due to less than five expected cases in at least one of the groups in all cross-tables. Statistical analysis of all characteristics was also performed between patients that had an increase in CTC number/% MAF after compression with patients that did not have an increase in CTC number/% MAF after compression. A non-parametric Wilcoxon signed-rank test was applied to test for CTC differences/% MAF changes between before and after compression. For comparison between central and peripheral CTC/ctDNA measurements, a sign test was used.

All statistical analyses were performed in IBM SPSS Statistics (version 24, IBM, Armonk, NY, USA) and *p* values \< 0.05 were considered significant.

Results {#Sec8}
=======

In total, 8/31 patients (26%) had ≥ 1 CTC in at least one of the blood samples taken before or after mammographic breast compression (Fig. [1](#Fig1){ref-type="fig"}). Correspondingly, 13/20 patients (65%) had ≥ 0.01% MAF and were defined as ctDNA positive. No agreement was found between CTC- and ctDNA-positive patients (κ = 0.02, *p *= 0.92) (A plot of CTC count versus % MAF can be found in supplementary Fig. S1).Fig. 1Examples of CTCs detected with the CellSearch system from a patient in the study

Patient and tumor characteristics of the whole cohort, as well as of CTC/ctDNA-positive and CTC/ctDNA-negative patients separately, are shown in Table [1](#Tab1){ref-type="table"}. No patient or pathologic characteristics were statistically associated with CTC positivity. Larger tumor size, non-ductal histological subtype, and older age were more predominant in the CTC-positive group but the difference was not statistically significant. ctDNA positivity was associated with higher age (*p *= 0.05). Higher Ki67, ductal histological type, and triple-negative breast cancer were more predominant in ctDNA-positive patients, without reaching statistical significance (Table [1](#Tab1){ref-type="table"}). Notably, 4/4 triple-negative breast cancers (TNBC) and 4/4 T4 staged cancers were all ctDNA positive.Table 1Comparison of patient and tumor characteristics between patients positive for CTCs and ctDNA (≥ 1 CTC/≥ 0.01% MAF) and patients with no CTCs/% MAFTotal (*N *= 31)CTC negative (*N *= 23)CTC positive (*N *= 8)*p* valueTotal (*N *= 20)ctDNA negative (*N *= 7)ctDNA positive (*N *= 13)*p* valueAge (years)Median (range)50 (33--74)47 (33--74)56 (43--71)0.21^a^51 (35--74)46 (35--62)58 (40--74)0.05^a^  \< 50161330.43^b^10550.35^b^  ≥ 50151051028Tumor size and stage Median size, mm (range)30 (4--90)30 (4--90)38 (16--80)0.21^a^30 (4--80)24 (8--80)30 (4--80)0.60^a^ T1 (\< 20 mm)8710.64^b^6330.61^b^ T2--T4 (20 mm or higher)2316714410Nodal stage N04311.0^b^2020.52^b^ N+2720718711ER Negative (10% or lower)8621.0^b^4040.25^b^ Positive (\> 10%)231761679HER2 Negative251871.0^b^175120.27^b^ Positive651321Ki67 Median % of cells stained (range)45 (15--95)45 (20--95)49 (15--90)0.61^a^40 (15--90)30 (15--90)45 (20--90)0.19^a^ Low (20% or lower)3211.0^b^3121.0^b^ High (\> 20%)2821717611Breast cancer subtype ER+181260.63^b^13580.20^b^ HER2+651321 TNBC761404Multifocality No221750.64^b^154110.29^b^ Yes853532 Missing11Histological subtype Ductal231940.15^b^133100.17^b^ Other844743Detection mode Screening9721.0^b^8260.64^b^ Symptomatic221661257^a^Mann--Whitney *U*-test^b^Fisher's exact test

Thirty patients had CTC results from the central blood sample before and after breast compression and 22 of these patients had 0 CTCs at both time points. Five of eight patients with detectable CTCs had an increased number of CTCs after compression (*p *= 0.19) (Fig. [2](#Fig2){ref-type="fig"}a). The average CTC increase was 3.2 cells (median 1.0 cell). Only two evaluable patients had detectable CTCs in the peripheral blood sample (Fig. [2](#Fig2){ref-type="fig"}b). Both central and peripheral % MAF generally increased after compression with the latter reaching significance (*p *= 0.08 and *p *= 0.01) (Fig. [2](#Fig2){ref-type="fig"}c, d). The average increase of % MAF was relatively small, 0.77 and 0.35 (median 0.35 and 0.22% MAF) for central and peripheral, respectively. Of the 20 patients with assessable ctDNA samples before and after breast compression, eleven and eight patients had 0% MAF in central and peripheral plasma samples, respectively, at both time points.Fig. 2The number of CTCs found before and after mammographic breast compression in central venous access (**a**), where two patients are represented by a line going from 0 to 1 CTC and from 1 to 0 CTCs, respectively. The corresponding number of CTCs before and after compression in peripheral blood (**b**). Figures for mutant allele frequency before and after breast compression in central (**c**), where two patients are represented by a line from 0 to approximately 0.35, and peripheral (**d**) plasma, where two patients are represented by a line going from 0 to approximately 0.04 and from approximately 0.03 to 0, respectively. Patients with an increasing value are plotted with red lines, decreasing values in blue, and constant values in green. All patients that did not have any circulating tumor markers are summarized in one line at number/frequency = 0

The median fraction of Ki67-positive cells was 66% (range 30--90%) in the five patients that had an increase in CTC number after compression, compared to 45% (range 15--95%) in patients with no increase (*p *= 0.31) (Supplementary Table 1). Also, Ki67 fraction was significantly higher in the group with increasing ctDNA after compression, 45% versus 30% (*p *= 0.04) (Supplementary Table 2). No other factors were differentially expressed between patients with an increase in CTCs/ctDNA levels and patients with a stable or a decrease in CTCs/ctDNA levels after compression. However, the histological type of the primary tumor seemed to differ between patients with an increase in the number of CTCs and patients with an increase in the levels of ctDNA after compression (Supplementary Tables 1 and 2).

CTCs were more abundant in central compared to peripheral blood in 8/10 positive samples (*p *= 0.04) (Fig. [3](#Fig3){ref-type="fig"}a). Forty-nine comparisons between central and peripheral blood contained 0 CTCs in both samples. There was no significant difference in % MAF levels between central and peripheral sampling (8/20 favoring higher % MAF in the central blood sample, *p *= 0.50) (Fig. [3](#Fig3){ref-type="fig"}b). Twenty comparisons between central and peripheral blood contained 0% MAF in both samples.Fig. 3CTC (**a**) and ctDNA (**b**) detection in central and peripheral sample pairs. In 8/10 CTC-positive pairwise samples, a higher number of CTCs was detected in the central compared to the peripheral blood sample (*p* = 0.04). In pairwise samples 1--6, no CTCs were found in the peripheral blood sample. In 12/20 ctDNA pairwise samples, a higher mutant allele fraction was found in the peripheral plasma sample (*p* = 0.50). In pairwise samples 2, 4--7, no ctDNA was detected centrally, and in sample 1, no ctDNA was detected peripherally

Discussion {#Sec9}
==========

CTCs were detected in 26% of the patients before start of neoadjuvant therapy for primary breast cancer. This is in line with a recent meta-analysis where 25.2% of breast cancer patients had CTCs before onset of neoadjuvant chemotherapy (deemed independent of blood sampling volume) \[[@CR2]\]. ctDNA was positive in 65% of the patients. The concordance between CTCs and ctDNA has been shown to be higher in metastatic breast cancer patients \[[@CR29]\] as compared to what was found in this study, which is most likely due to the lower rate of CTCs in primary breast cancer (Supplementary Fig. S1). ctDNA positivity, defined as ≥ 0.01% MAF in this study, was associated with higher age (*p *= 0.05) and a trend was noted that a more aggressive tumor phenotype, including high Ki67, TNBC, and T4 staged cancers, favors ctDNA positivity (not statistically significant).

For CTCs, no increase was seen in either central or peripheral blood after mammographic breast compression (*p *= 0.19 and *p *= 0.37, respectively). However, both central and peripheral ctDNA levels increased after breast compression (*p *= 0.08 and *p *= 0.01, respectively). Only one patient had a CTC count difference of \> 5 cells/7.5 ml between samples taken before and after compression (Fig. [2](#Fig2){ref-type="fig"}a). This suggests a lack of a larger bolus release of cells during breast compression of women with primary breast cancer. The central blood samples were drawn on average 2 min after compression and, according to an animal study, the release of malignant cells starts at the manipulation procedure and stays elevated up to 60 min \[[@CR19]\]. To the best of the authors' knowledge, no published study has investigated how ctDNA levels vary with manipulation of a primary tumor with regard to applied pressure. The increase of ctDNA after breast compression found in this study can be considered relatively small, with only one case going from % MAF 0.95 to 2.36 which possibly could affect prognostication (Fig. [2](#Fig2){ref-type="fig"}d) \[[@CR8]\]. High Ki67 were associated with increased ctDNA levels (*p *= 0.04) (Supplementary Table 2).

As hypothesized, CTCs were in general significantly more likely to be present in central than in peripheral blood samples (*p *= 0.04). Six patients presented CTCs only in the central samples (Fig. [3](#Fig3){ref-type="fig"}a) suggesting a differential CTC yield depending on sample location. The results are comparable to the work by Peeters et al. \[[@CR23]\] in metastatic breast cancer but no data from studies involving differential blood sampling of primary breast cancer are hitherto available. This differential yield was not seen for ctDNA (*p *= 0.50). Since ctDNA is a much smaller moiety and soluble in the blood, we speculate that ctDNA is much less affected by physical hindrance in the capillaries as compared to CTCs. Hence, ctDNA blood sampling is independent of blood drawing location, a finding that could contribute to the definition of clinical sampling routines in primary breast cancer for ctDNA.

The major limitation of this study was the small sample size and low count of CTCs, despite that a total of up to 40 ml whole blood was drawn from each patient. The statistical nature of CTC sampling has been described by Tibbe et al. \[[@CR5]\]. Due to the low sample size, a possible difference between CTCs detection before and after breast compression may have been underestimated. Similarly, the ctDNA analysis was limited by a relatively low plasma input volume, and therefore a limited number of genome equivalents being analyzed for the presence of mutations.

When CTCs and ctDNA markers are implemented into clinical routine, our understanding of how the concentrations fluctuate during different interventions should be better understood. The women in this cohort are continuously being monitored and follow-up data will be available and presented in future publications.

Conclusion {#Sec10}
==========

In summary, there was no significant release of CTCs after mammographic breast compression but more CTCs were present in central compared to peripheral blood. There was a small average increase in ctDNA levels after breast compression, unlikely to be clinically relevant, and no difference between central and peripheral levels was found.
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